A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Homeostatic iron regulator gene-related hereditary hemochromatosis
Спонсор: CSL Behring LLC
Налично на:
БГ
Обобщение
Trial status: Authorised
Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) ,
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 25 participants
БГ
EN